Tauriga Sciences, Inc. Fully Repays $40,000 USD Face Value Convertible Debenture for One Time Cash Payment of $59,658.96 USD
BUZ INVESTORS PRESS RELEASE Tauriga Sciences, Inc Tauriga Sciences, Inc. ( OTC PINK : TAUG ) (“Tauriga” or the “Company”), engaged in building of businesses in the life sciences space, today announced that is has fully repaid and retired a $40,000 USD face value 12.00% convertible debenture held by Group 10 Holdings, LLC. This convertible debenture, which was issued by the Company on March 31, 2017, has been fully repaid for a one-time cash payment of $59,658.96 USD. Accordingly, this debt will be removed from the Company’s balance sheet.
The Company’s management and Board of Directors have established a long term corporate goal to be completely free of convertible debt. Significant efforts will be made by the Company moving forward to retire additional tranches of its existing convertible debt.
Tauriga Sciences, Inc
Tauriga’s Chief Executive Officer, Seth M. Shaw, expressed, “The Company is working diligently to curtail potential future share dilution and is pleased to have repaid this convertible debenture for this one-time cash payment. The Company continues to believe that it is making important progress on a number of strategic initiatives, including the anticipated launch of its Cupuacu Butter lip balm product. My recent personal investments into the Company should underscore my belief in our future prospects and my commitment to both restore and create long term value for our loyal shareholder base.”
ABOUT TAURIGA SCIENCES, INC.
Tauriga Sciences, Inc. ( OTC PINK : TAUG ) is a fully reporting life sciences company engaged in the development, marketing, distribution and potential licensing of a broad array of products and technologies that may help individuals who are affected by muscle tension. The Company has already identified potential products and technologies of interest and is actively working towards the goal of creating an innovative product line to launch the business activities of ColluMauxil Therapeutics LLC. The Company believes that one of its most important strengths is its access to and relationships with potentially substantial distribution systems and networks. The Company intends to capitalize on distribution opportunities and will continually update shareholders on such developments. The Company is also prosecuting (as Plaintiff) its ongoing malpractice lawsuit against its predecessor audit firm, for which it’s seeking monetary damages in excess of $4,500,000 USD.
This press release does not constitute an offer to sell or the solicitation of an offer to buy any of these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale is not permitted. Any securities offered or issued in connection with the above-referenced merger and/or investment have not been registered, and will be offered pursuant to an exemption from registration.